Skip to main content
Login
Contact
Subscribe
Search form
Search
Mammoth Times
Click for weather forecast
Home
Forms
News
Obituaries
Sports/Outdoors
Classifieds
Place an Ad
Photos
Videos
Games
Mountain
Snow Report
Ski Report
Road Conditions
Entertainment
Local Guide
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Aimmune Therap
(NQ:
AIMT
)
34.49
USD
UNCHANGED
Last Price
Updated: 7:11 PM EDT, Oct 12, 2020
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Aimmune Therap
< Previous
1
2
3
4
5
6
7
Next >
Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings
October 19, 2017
Aimmune Therapeutics to present data on peanut allergy at ACAAI and PAAM medical meetings.
From
Business Wire News Releases
Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
October 16, 2017
Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy
From
Business Wire News Releases
Aimmune Therapeutics to Participate in Three Investor Conferences in September
September 06, 2017
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team...
From
Business Wire News Releases
Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
August 09, 2017
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview...
From
Business Wire News Releases
Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
August 08, 2017
Aimmune Therapeutics reports financial results for the second quarter ended June 30, 2017.
From
Business Wire News Releases
Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy
August 08, 2017
Aimmune's AR101 for peanut allergy in Science Translational Medicine article by Benaroya Research Institute on new TH2 subset specific to allergy.
From
Business Wire News Releases
Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
July 05, 2017
Aimmune Therapeutics enrolls first patient in ARTEMIS (ARC010) European Phase 3 clinical trial of AR101 for the treatment of peanut allergy.
From
Business Wire News Releases
Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
June 19, 2017
Aimmune Therapeutics presents European Phase 3 PALISADE screening data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress.
From
Business Wire News Releases
Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
June 15, 2017
Aimmune Therapeutics will present data on peanut allergy in Europe at the 2017 EAACI Congress in Helsinki on Tuesday, June 20.
From
Business Wire News Releases
Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
June 12, 2017
Aimmune Therapeutics reports on up-dosing in its ongoing Phase 3 trial of AR101 in patients with peanut allergy.
From
Business Wire News Releases
Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th
June 08, 2017
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview...
From
Business Wire News Releases
Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy
June 07, 2017
Aimmune Therapeutics celebrated the completion of its commercial manufacturing facility in Clearwater, Florida, which will support the potential launch of AR101 treatment for peanut allergy.
From
Business Wire News Releases
Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
May 11, 2017
Aimmune Therapeutics enrolls first patient in RAMSES, a Phase 3 clinical trial of AR101 for the treatment of peanut allergy
From
Business Wire News Releases
Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
May 09, 2017
Aimmune Therapeutics will present at the Bank of America Merrill Lynch Healthcare Conference on May 16th at 1 p.m. Pacific Time.
From
Business Wire News Releases
Aimmune Therapeutics Announces First Quarter 2017 Financial Results
May 08, 2017
Aimmune Therapeutics announces first quarter financial results.
From
Business Wire News Releases
Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
April 12, 2017
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the appointment of Eric Bjerkholt as Chief Financial Officer.
From
Business Wire News Releases
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
March 15, 2017
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today...
From
Business Wire News Releases
Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
March 08, 2017
Aimmune Therapeutics will announce 4Q and full year 2016 financial results on March 15, 2017, before U.S. markets open.
From
Business Wire News Releases
Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
March 06, 2017
Aimmune presented clinical data for AR101 for peanut allergy at AAAAI, including insights from Phase 3 screening (largest screening data set ever collected) and Phase 2 data supporting 95% adherence.
From
Business Wire News Releases
Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
March 01, 2017
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today...
From
Business Wire News Releases
Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
February 27, 2017
Aimmune will present AR101 clinical data in peanut allergy at the 2017 AAAAI annual meeting on March 6 in Atlanta, Georgia.
From
Business Wire News Releases
Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
February 16, 2017
Aimmune provides update on AR101 Phase 3 program for peanut allergy based on FDA feedback; program to initially address ages 4-17, consistent with Breakthrough Therapy Designation patient population.
From
Business Wire News Releases
Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 04, 2017
Aimmune Therapeutics to present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, at 5 p.m. Pacific Time.
From
Business Wire News Releases
Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts
November 30, 2016
Aimmune announced its Scientific Advisory Board of leading food allergy researchers: Dr. Kirsten Beyer, Dr. A. Wesley Burks, Dr. Thomas Casale, Dr. Jonathan Hourihane, and Dr. Stacie Jones.
From
Business Wire News Releases
Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
November 28, 2016
Aimmune Therapeutics announced that it has completed global enrollment of its Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy.
From
Business Wire News Releases
Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science
November 28, 2016
Aimmune Therapeutics closes $145 million investment by Nestle Health Science
From
Business Wire News Releases
Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy
November 21, 2016
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today...
From
Business Wire News Releases
Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
November 14, 2016
Aimmune announces financial results for 3Q 2016 and provides a corporate update.
From
Business Wire News Releases
Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics
November 04, 2016
Aimmune Therapeutics announces $145 million equity investment by Nestlé Health Science, demonstrating shared commitment to advancing food allergy therapeutics.
From
Business Wire News Releases
Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences
October 31, 2016
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today...
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
X
Username
*
Password
*
Request new password